SK 01
Alternative Names: SK-01Latest Information Update: 28 Aug 2024
At a glance
- Originator University Medical Center Utrecht
- Developer Synerkine Pharma
- Class Analgesics; Antirheumatics; Recombinant fusion proteins
- Mechanism of Action Interleukin 10 receptor modulators; Interleukin 4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoarthritis; Pain
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Osteoarthritis in Netherlands
- 28 Aug 2024 No recent reports of development identified for preclinical development in Pain in Netherlands
- 25 Mar 2019 Preclinical trials in Osteoarthritis in Netherlands (unspecified route)